Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Plos One|September 10, 2013
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trialDenis R Chopera, Jaclyn K Mann, Philip Mwimanzi, et al.
Scientific Reports|March 4, 2017
The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assaysRachel Tanner, Matthew K O'Shea, Andrew D White, et al.
Pigment Cell & Melanoma Research|June 30, 2023
Prognostic biomarkers for survival in mucosal melanomaJulia C Thierauf, Stefan T Kaluziak, Elizabeth Codd, et al.
Scientific Reports|April 5, 2019
Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assaysRachel Tanner, Matthew K O'Shea, Andrew D White, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2014
The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum womenVivek Naranbhai, Dhayendre Moodley, Tsungai Chipato, et al.
The Lancet. Oncology|December 13, 2021
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker studyVivek Naranbhai, Mathias Viard, Michael Dean, et al.
Cell|March 20, 2021
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunityWilfredo F Garcia-Beltran, Evan C Lam, Kerri St Denis, et al.
Medrxiv : the Preprint Server for Health Sciences|February 23, 2021
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunityWilfredo F Garcia-Beltran, Evan C Lam, Kerri St Denis, et al.
JAMA Dermatology|January 12, 2022
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 TherapyKimberly Tang, Jayhyun Seo, Bruce C Tiu, et al.
The Journal of Allergy and Clinical Immunology. Global|March 28, 2024
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response in adults with predominantly antibody deficiencyAnna M Zhang, Ahmed Elmoursi, Daniel V DiGiacomo, et al.
Pageof 10